2Strands Named One of LSI Asia 2026’s “Five Innovators to Watch”

2Strands Biosciences presented ultra-sensitive ctDNA detection technology at LSI Asia 2026, sharing its approach to advancing cancer recurrence monitoring with investors, entrepreneurs, industry leaders and fellow MedTech innovators.

The event provided a valuable platform to exchange insights on the continued growth of MedTech innovation across the Asia-Pacific region and explore opportunities for collaboration.

2Strands was also recognised by LSI as one of “Five Innovators to Watch”, selected from more than 70 presenting companies at the conference. This recognition reflects the growing interest in technologies with the potential to transform how cancer recurrence is monitored and managed.

Read more at https://www.linkedin.com/pulse/analyst-report-lsi-asia26-innovators-watch-duzcc/